Via Carpe Diem comes Donald J. Boudreaux at the Wall Street Journal who presents the case for repealing the meddlesome laws relating to insider trading:
The insider who learns that the Food and Drug Administration will approve a new blockbuster drug developed by a major drug company, for example, obviously profits from this information if it prompts him to buy 1,000 shares of the company that he otherwise wouldn’t have bought. So, too, though, does the insider profit who, upon learning the same information, abandons her plans to sell 1,000 shares of the company. But because insider "nontrading" is undetectable, only the former insider is practically subject to prosecution and punishment.
It’s an aspect I hadn’t considered before, but there’s other arguments for the proposition, so read ’em.
And peruse the comments at the first link above to read the horrors in the hearts of those imagining the bogeyman of unfettered capitalism hiding in the closet.
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | ||||||